Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC meeting planned

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to hold a public hearing on direct-to-consumer promotion of medical products, including medical devices, Nov. 1-2 in Washington, D.C. "Medical device DTC promotion has not yet received as much FDA attention because, until recently, there has not been a significant amount of DTC device promotion," the agency notes in a Sept. 13 Federal Register notice. FDA points to "recent increases in DTC device promotion and a growing awareness among consumers that medical devices may give them important choices." Those interested in participating must contact FDA by Oct. 11...

You may also be interested in...



Firms Should Heed Where Third-Party Web Links Are Posted – FDA’s Wolf

Firms providing access to independent websites should provide the links on centralized corporate pages rather than on product-specific Internet sites, FDA's Office of Compliance staffer Deborah Wolf suggested Sept. 20

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel